B. Riley raised the firm’s price target on OptimizeRx (OPRX) to $28 from $18 and keeps a Buy rating on the shares. The firm views the company’s Q3 report as strong.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $24 from $23 at Citizens JMP
- OptimizeRx Reports Strong Q3 Growth and Raises Guidance
- OptimizeRx: Strong Financial Performance and Promising Outlook Justify Buy Rating
- OptimizeRx reports Q3 EPS 20c, consensus 5c
- OptimizeRx raises FY25 revenue view to $105M-$109M from $104M-$108M